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Background: Despite the clinical success of vascular endothelial growth factor (VEGF) blockade in
metastatic colorectal cancers (mCRC), resistance to anti-angiogenic drugs invariably develops. IL-8 and
other cytokines have been implicated in development of resistance to anti-angiogenic therapy. Levocetirizine
is a second generation H1 antihistamine with anti-inflammatory and IL-8 suppression properties. We
conducted a phase II trial combining levocetirizine with capecitabine and bevacizumab to potentially
overcome anti-angiogenic therapy resistance in patients with refractory mCRC.
Methods: This was a single-center open-label prospective trial in refractory mCRC patients. Treatment
consisted of oral capecitabine 850 mg/m2 twice daily administered as 7 days on and 7 days off, intravenous (IV)
bevacizumab 5 mg/kg every 14 days and oral levocetirizine 5 mg daily. The primary end point was progression
free survival (PFS) and secondary endpoints included objective response rate (ORR) and tolerability. An
exploratory endpoint included correlation of PFS with cytokine levels. A sample size of 36 evaluable patients
could identify a median PFS of 3.4 months at a 0.05 significance level. To examine cytokine changes related
to levocetirizine treatment, patients were randomized to Arm A where levocetirizine was started 7 days after
starting chemotherapy and to Arm B where levocetirizine was started 7 days prior to chemotherapy. Cytokine
levels were measured at baseline and with each cycle of chemotherapy (up to three cycles).
Results: Forty-seven patients were enrolled in the trial to have 36 evaluable patients. Arm A enrolled
23 patients and Arm B enrolled 24 patients. Fifty percent of patients had progressive disease and 62% of patients
had stable disease in each arm as best response. There was no demonstrable difference in PFS between the two
arms (log-rank test P=0.83). Median time to progression was 3.4 months in Arm A and 3.5 months in Arm B.
Conclusions: Median PFS in the trial was comparable to and appeared to be better than other regimens
used in the refractory setting (e.g., median PFS of 1.9 months for regorafenib). Cytokine measurement
with IL-8 levels did not show any correlation with progression free survival but patients with stable disease
showed overall lower levels of IL-8 as compared to patients with progressive disease in the cytokine analysis.
Keywords: Levocetirizine; cytokine IL-8; anti-angiogenic resistance; metastatic colorectal cancer
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Introduction
Colorectal cancer is currently third most common cancer
and third leading cause of cancer-related death in the
United States. It is estimated that 140,250 new cases
of colorectal cancer will be diagnosed and 50,630 men
and women will die of colorectal cancer in 2018 (1).
Approximately 20% of patients will have distant disease at
the time of presentation and of the remaining, 50–60% will
develop metastatic disease (2). Current treatment options
for metastatic colorectal cancer include FOLFOX (5-FU/
leucovorin oxaliplatin), FOLFIRI (5-FU/leucovorin and
irinotecan) chemotherapy with either angiogenesis inhibitor
bevacizumab or an EGFR inhibitor such as cetuximab
or panitumumab depending upon the RAS status (3-14).
Combination of FOLFIRI plus aflibercept, FOLFIRI plus
ramucirumab, regorafenib, trifluridine/tipiracil, nivolumab
and pembrolizumab for MSI- H colorectal cancers are also
FDA approved for second line or later in the treatment of
metastatic colorectal cancer (13,15-21). Addition of all the
novel agents to the current chemotherapy, has increased
median overall survival of patients with advanced colorectal
cancer currently approaching three years (22). Despite
significant advancements in the management of metastatic
colorectal cancer, prognosis of metastatic colorectal cancer
remains poor after progression of disease on first-line
therapy (23).
Our study was initiated after FDA approval of
regorafenib but prior to FDA approvals of trifluridine/
tipiracil, nivolumab and pembrolizumab for metastatic
refractory colorectal cancer. Patients in our trial were
considered refractory to the available chemotherapy options
at that time and to preserve quality of life, we decided to use
a regimen of oral capecitabine one week on and one week
off and IV bevacizumab every 14 days which is considered as
clinically active, is feasible to administer and also tolerable
to the patients (24). A capecitabine dose of 850 mg/m2 BID
was considered since all of our patients had progression on
full dose fluorouracil and or capecitabine chemotherapy and
a lower dose seemed feasible to administer as maintenance
as well as to preserve quality of life.
Angiogenesis is required for tumor growth and
metastases of colorectal cancer. Even though antiangiogenic drugs have had a significant impact on
treatment outcomes in patients with colorectal cancers,
eventually all patients in the metastatic setting develop
disease progression, presumably due to tumor resistance
to anti-angiogenic therapy and chemotherapy (25). Two
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modes of resistance to anti-angiogenic therapy have been
proposed. Intrinsic resistance is defined by the absence
of any beneficial effect of anti-angiogenic therapy, even a
transitory one leading to no tumor response to therapy.
Whereas, adaptive (evasive) resistance refers to the ability
of the tumor, after an initial response phase, to develop
an adaptation to circumvent specific angiogenic blockade.
One of the mechanisms of evasive resistance to an antiangiogenic regimen involves upregulation of alternative
pro-angiogenic signaling pathways. Blocking one of these
alternate pathways may affect a tumor’s ability to continue
to grow and metastasize (26,27). IL-8 is a cytokine, derived
by monocytes and macrophages. Few studies have implied
the role of IL-8 in angiogenesis as well as in causing
resistance to anti-angiogenic chemotherapy agents. A study
by Koch et al. demonstrated that human recombinant
IL-8 showed angiogenic activity by inducing proliferation
and chemotaxis of human umbilical vein endothelial cells.
The study also showed that, antibodies to IL-8 blocked
the angiogenic activity in human rheumatoid synovial
tissue macrophages, demonstrating the role of IL-8 in
angiogenesis (28). Another study by Huang et al. has shown
that IL-8 may be responsible for causing resistance to antiangiogenic chemotherapy agents. Sunitinib, is an antiangiogenic targeted agent approved for the treatment
of clear cell renal cell carcinoma (RCC). But, patients
develop resistance to sunitinib within a year causing
further progressive disease (29). This study by Huang
et al. developed xenograft models representing sunitinib
resistance in RCC. Sunitinib resistant tumors showed
increased secretion of IL-8 and administration of IL-8
antibody re-sensitized the tumors to sunitinib treatment,
demonstrating the role of IL-8 not only in angiogenesis
but also causing resistance to anti-angiogenic agents (30).
IL-8 has been shown to be associated with proliferation,
migration, angiogenesis and chemo-sensitivity in vitro and
in vivo in colon cancer cell lines models (31). IL-8 and its
receptor CXCR2 are demonstrated to be upregulated in
colorectal cancer and has been shown to impact in vivo
angiogenesis as well as migration, invasion and proliferation
of colorectal cancer cells and hence are an excellent
therapeutic target (32).
Levocetirizine is a third-generation, potent, non-sedating
anti-histamine (33,34). Levocetirizine has extensive welldocumented anti-inflammatory properties, inhibiting IL-8,
and NF-κB in vivo (35). In vitro, levocetirizine inhibits the
secretion of IL-6 and IL-8 and inhibits the upregulation of
NF-κB (36).
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We conducted this trial to treat patients with refractory
colorectal cancer with a combination regimen including
capecitabine plus bevacizumab, an anti-angiogenic agent
and added an IL-8 inhibitor, levocetirizine, to study the
effects on patients’ tumor response and the systemic
cytokine profile. The primary endpoint of the trial was
to determine median progression-free survival in patients
treated with this combination. The secondary endpoint
included evaluation of tolerability of this regimen and
an exploratory endpoint was to evaluate the relationship
between the cytokine profile and response or resistance to
anti-angiogenic therapy.
Methods
Patients and study design
This was a randomized single institutional phase II trial.
Eligibility criteria included histologically or cytologically
confirmed diagnosis of CRC, measurable progressive
disease refractory to prior therapy with fluoropyrimidine,
oxaliplatin, irinotecan, and/or anti-angiogenic therapy
and epidermal growth factor receptor (EGFR) inhibitor
such as cetuximab or panitumumab for KRAS wild type
tumors. Other inclusion criteria included adequate bone
marrow and organ function and ECOG of <2. Patients with
active brain metastasis, dihydropyrimidine dehydrogenase
(DPD) deficiency, uncontrolled hypertension, proteinuria,
unstable angina and known HIV status on highly active
antiretroviral therapy (HAART) were excluded from the
trial due to possible interaction of levocetirizine with
HAART medications. The study protocol, NCT01722162
and ethics approval was obtained from Washing University
Institutional Review Board (IRB) and was allotted with
Human Research Protection Office (HRPO) number
#201303043 and all the participants gave informed consent
before participating in the trial.
Treatment plan
Patients were randomized to one of two arms: patients
in Arm A initiated the therapy with bevacizumab +
capecitabine and started taking levocetirizine daily on Day
8 of Cycle 1. Patients in Arm B initiated levocetirizine daily
7 days prior to initiation of therapy with bevacizumab +
capecitabine (Day-7).
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Drug administration
Bevacizumab was given IV on an outpatient basis at a dose
of 5 mg/kg on Day 1 of each 2-week cycle. Capecitabine
was given orally at a dose of 850 mg/m2 twice a day on Days
1–7 of each 2-week cycle. Levocetirizine was also given
orally at a dose of 5 mg daily before bed. Patients were
followed every 2 weeks up to 30 days after progression of
disease, or until death, whichever occurred first.
Assessment
Patients received CT scans at baseline and at every 8 weeks.
Response and progression were evaluated by using Response
Evaluation Criteria in Solid Tumors (RECIST) guideline
version 1.1. All adverse events and toxicity grading report was
done according to the revised NCI Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
Statistical consideration
The study randomization (Arm A and Arm B) was to assess
the systemic cytokine response. The primary end point was
progression free survival (PFS) and secondary endpoints
included ORR and tolerability. Since all patients received
the same overall therapy, both arms were combined in
evaluating the incidence and severity of adverse events.
Expected effect size, sample size and study power
Phase III randomized double-blind, placebo-controlled
multicenter trial (CORRECT) (21), results showed that the
median PFS in patients with metastatic colorectal cancer
who had progression during or less than three months
after their last standard therapy was 1.7 months. Based
on this historical control, we proposed a favorable PFS
of 3.4 months for our study regimen (IL-8 inhibitor plus
capecitabine and bevacizumab). With a sample size of 36
evaluable patients (Arms A and B combined) the study had
the power ≥0.90 to identify a doubling of median PFS (1.7
to 3.4 months) at a 0.05 significance level. The proposed
sample size also had the power ≥0.80 to identify a difference
between median PFS of 1.7 and 3.0 months at the same
significance level. The sample size of 36 evaluable patients
seemed adequate for the primary aim and included a margin
for error such that the minimal detectable difference with
36 patients is an increase of 75% in median PFS.
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Analysis plan
Cox proportional hazards models were used to estimate
median PFS with a 95% confidence interval. Binomial
proportions and 95% confidence intervals were used
to describe the incidence of adverse events. Chi-square
goodness-of-fit tests was used to test for increased severity
(grade) of adverse events, especially of grades 3 and 4 over
1 and 2. Tables and multidimensional plots were used to
illustrate cytokine expression by study arm, and multiplicity
corrected t-tests or Wilcoxon rank sum tests were used to
test for differences between study arms.
Correlative studies
Cytokine measurement: collection of specimen(s)
A total of 6 mL of blood was collected in 2 EDTA tubes in
Arm A prior to initiation of capecitabine and bevacizumab
(baseline or Cycle 1 Day 1) and prior to initiation of
levocetirizine (Cycle 1 Day 8) and in Arm B prior to
initiation of levocetirizine (baseline or Day-7) and prior to
initiation of capecitabine and bevacizumab (Cycle 1 Day 1).
Blood for cytokine measurement was also collected in both
the arms on cycle 2 Day 1, prior to infusion of bevacizumab
and on cycle 3 Day 1, prior to infusion of bevacizumab.
Cytokines were measured with ELISA method from R&D
Systems as per protocol by Ciprandi et al. (37).
Results
Study population
Forty-seven patients were consented for the trial from
4/26/2013 until 7/15/2015. Five patients in Arm A and six
patients in Arm B were not enrolled (NE) due to either
insurance denial, disease progression prior to starting the
trial or withdrawal of consent or a trial unrelated adverse
event. Thirty-six evaluable patients were randomly assigned
to Arm A and Arm B and treated per trial protocol. Table 1
demonstrates the baseline characteristics of all 47 patients
in Arm A and B. Median age on the trial was 60 years.
Majority of the patients had a history of colon cancer with
prior history of surgical resection. All the patients on the
trial had received at least two or more lines of systemic
chemotherapy prior to their enrollment. Nineteen percent
of patients had history of rectal cancer and had received
neoadjuvant chemoradiation and surgical resection as a part
of their initial treatment. KRAS was mutated in 24 out of 47
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patients. KRAS status was unknown in one patient. Eighty
percent of patients had more than one site of metastatic
disease. Forty-five out of 47 patients had prior bevacizumab
exposure and all 36 patients included in the efficacy analysis
had prior bevacizumab therapy.
Efficacy
All 36 patients on the trial had either progression of their disease
or had died, hence, there were no censored (alive at last follow
up) observations in the model of progression-free survival.
Table 2 demonstrates efficacy and PFS in arm A and arm B.
Median PFS was 3.36 months in Arm A and 3.5 months in Arm
B. Twenty patients out of 36 (55%) showed stable disease.
Figure 1 shows a Kaplan Meier survival curve demonstrating
PFS in both Arm and Arm B. The curves overlap indicating
similar PFS in both arms of the study.
Toxicity
Table 3 describes all adverse events including grade 3 and 4
adverse events related to the treatment. Treatment-related
death did not occur in any of the arms in the trial. The
majority of the patients tolerated this regimen very well.
The most common side effects were grade 1 constipation,
nausea, diarrhea, vomiting, abdominal pain, fatigue,
headaches and cough as shown in Table 3. There were no
grade 4 adverse events in Arm A but 1 patient in Arm B
suffered respiratory failure which was considered grade 4
adverse event related to progressive disease. The adverse
event profile of the combination study regimen was within
the expected margins of this regimen. There were no new,
unanticipated toxicities noted.
Correlative studies
Collection of cytokine IL-8 levels were attempted on all 36
evaluable patients. Blood samples of four patients in Arm A
and five patients in Arm B were considered non-measurable
due to either missing samples or due to processing delays
of the blood samples. Figure 2 and Figure 3 show the IL-8
levels across Arm A and Arm B respectively. One patient in
Arm B had cytokine IL-8 levels four-fold higher than mean
IL-8 levels across Arm B. Figure 4 shows the best response
by IL-8 levels in both arms combined. In general IL-8 levels
were greater in patients with progressive disease than those
with stable disease.
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Table 1 Patient baseline characteristics (N=47)
Characteristics

N

%

Arm A

Arm B

Male

29

61.7

14

15

Female

18

38.3

9

9

Median age

60

62

58

Sex

Location of primary tumor
Colon

30

63.8

15

15

Rectum

9

19.1

3

6

Rectosigmoid

8

17.0

5

3

Surgery

37

78.7

18

19

Prior >2 lines of chemotherapy

36

76.6

18

18

Radiotherapy

9

19.1

3

6

Bevacizumab

45

95.8

23

22

Mutated

24

51.1

14

10

Wild type

22

46.8

8

14

Unknown

1

2.1

1

–

Lung only

5

10.6

1

4

Liver only

4

8.5

3

1

Multiple (peritoneum, adrenal, abdominal
LN, chest LN, bone, brain, stomach, etc.)

38

80.9

19

19

Prior therapy

K-ras status

Metastatic site

LN, lymph nodes.

Table 2 Efficacy (N=47)
NE patients N

PD patients N [%]

SD patients N [%]

Total patients (N)

Median PFS in
months

95% CI

Arm A

5

8

10

23

3.36

1.41–5.66

Arm B

6

8

10

24

3.50

1.64–4.47

Total patients

11

16 [44]

20 [55]

47

–

–

Study Arm

NE, not evaluable; PD, progressive disease; SD, stable disease; PFS, progression free survival.

Discussion
Colorectal cancers are vascular tumors which rely on VEGF
mediated angiogenesis for tumor growth and progression.
VEGF expression by CRCs is associated with increased
metastasis and poor prognosis (38,39). Therapeutic blockade
© Journal of Gastrointestinal Oncology. All rights reserved.

of VEGF signalling has been successfully deployed as a
treatment strategy to treat metastatic CRC (mCRC) and
there are FDA approved drugs for the treatment of these
cancers that affect the angiogenesis pathway. Disappointingly,
however, all patients eventually develop resistance to antiangiogenic therapy and succumb to their cancer. Bevacizumab,
jgo.amegroups.com
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Study Arm
A
B

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
A 18
B 18

3
6
9
12
15
48
Months to progression, death or last follow-up
11
5
4
1
1
1
10
5
3
2
1

51
0

Figure 1 Progression free survival: summary of deaths and
progression events.

a humanized monoclonal antibody against VEGF, prevents
interaction between VEGF and VEGFR-2, acts as an antiangiogenic agent and is approved along with chemotherapy
as first and second line treatment for mCRC and contributes
to an improvement in overall survival. Capecitabine with
bevacizumab is an established and effective maintenance
regimen in metastatic colorectal cancer patients after induction
chemotherapy per phase III CAIRO 3 study (40). Our study
showed that, this regimen was also well tolerated in refractory
metastatic colorectal cancer patients and did not affect their
quality of life. None of the patients in our study discontinued
treatment due to regimen toxicity.
A number of mechanisms of resistance (26) to
antiangiogenic therapies have been described, including
the increased expression of various cytokines (IL-8, IL-6,

Table 3 Adverse events related to the treatment including grade 3 and grade 4 adverse events
Adverse events

Grade 1, n (%)

Grade 2, n (%)

Grade 3, n (%)

Heart failure

1 (2.78)

Colon fistula/perforation

2 (5.56)

Small bowel obstruction
Fatigue

1 (2.78)
15 (41.67)

6 (16.67)

2 (5.56)

Bacteremia

2 (5.56)

LFT abnormalities
Anorexia

3 (8.34)
12 (33.34)

1 (2.78)

UTI

1 (2.78)

Urinary retention

1 (2.78)

Generalized muscle
weakness

2 (5.56)

Neuropathy

2 (5.56)

Dyspnea

Grade 4, n (%)

8 (22.23)

1 (2.78)

Respiratory failure

1 (2.77)

Hypertension

3 (8.34)

Thromboembolic event

1 (2.78)

Abdominal pain

6 (16.67)

Constipation

11 (30.56)

Diarrhea

14 (38.89)

Nausea

14 (38.89)

Vomiting

10 (27.78)

Headache

9 (25.00)

Cough

10 (27.78)

Dry skin

8 (22.23)

Hand-Foot syndrome

6 (16.67)

3 (8.34)

2 (5.56)

5 (13.89)

LFT, liver function tests; UTI, urinary tract infection.
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300
SD
PD

300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
–20

275
250
225
IL-8 (pg/mL)

IL-8 (pg/mL)

IL-8, Arm A and best response

200
175
150
125
100
75
50
25

C1D1

C1D8

C2D1

0

C3D1

PD

Figure 2 IL-8 levels across Arm A. SD, stable disease; PD,
progressive disease.

IL-8 (pg/mL)

SD

Figure 4 IL-8 levels by best response in both arms combined.

IL-8, Arm B and best response
SD
PD

300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
–20

D-7

Best response

C1D1

C2D1

C3D1

Figure 3 IL-8 levels across Arm B. SD, stable disease; PD,
progressive disease.

IL-17, etc.) (31,41,42) and increased activity of immunemodulatory cells from the tumor microenvironment but
there are no known biomarkers to predict sensitivity
or resistance to anti-angiogenic therapies. We selected
levocetirizine, a potent anti-histamine, is commercially
available and has shown inhibition of IL-8 and NF-kB in
in vivo and in vitro studies (36,43,44).
In our study, fifty-five percent of patients on our study
had stable disease as best response. This was despite 100%
of patients with prior bevacizumab exposure. The PFS
was 3.5 months and was similar in both the arms of the
study. This PFS was better than other regimens used in
the refractory setting such as regorafenib and trifluridine/
tipiracil which showed median progression free survival of
3.2 and 2.0 months respectively (17,18).
Evaluation of cytokine IL-8 levels in our study did not show

© Journal of Gastrointestinal Oncology. All rights reserved.

any correlation with disease progression. In both arms, patients
with stable disease had lower levels of IL-8 at baseline and
throughout first three cycles of chemotherapy as compared to
patients with progressive disease. We used an ELISA method
to calculate circulating IL-8 levels, however, ELISA based
assays have their own limitations in terms of the quality of
antibody used as well as narrow dynamic range which may
have falsely reduced the concentration of circulating cytokine
in the blood due to a dilution effect (45). Also, ELISA results
may have been less precise due to our small sample size.
In conclusion, the regimen of levocetirizine with
capecitabine and bevacizumab was well tolerated by
refractory mCRC patients without any added toxicity from
levocetirizine. The combination of levocetirizine with
capecitabine and bevacizumab showed comparable PFS
estimates to other commonly used regimens. We were
unable to demonstrate an ability to overcome resistance
to anti-angiogenic therapy using a commercially feasible
cytokine inhibition strategy, a good avenue of investigative
therapeutic strategy to overcome angiogenic resistance.
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